Search details
1.
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Int J Cancer
; 155(1): 128-138, 2024 Jul 01.
Article
in English
| MEDLINE | ID: mdl-38447007
2.
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Onkologie
; 36(3): 95-100, 2013.
Article
in English
| MEDLINE | ID: mdl-23485996
3.
RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity.
J Biol Chem
; 286(3): 1976-86, 2011 Jan 21.
Article
in English
| MEDLINE | ID: mdl-21081503
4.
Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation.
J Cell Sci
; 123(Pt 13): 2163-9, 2010 Jul 01.
Article
in English
| MEDLINE | ID: mdl-20516151
5.
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Eur J Cancer
; 51(16): 2368-74, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-26276039
Results
1 -
5
de 5
1
Next >
>>